Combined Immune Checkpoint Blockade

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 656-662

  Drake, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; TUMOR ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL STUDY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; STUDY DESIGN; TESTIS CANCER; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84940367107     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.002     Document Type: Review

References (35)

1. C.J. Nirschl, and C.G. Drake Molecular pathways: Co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunorapy Clin Cancer Res 19 2013 4917 4934
2. A. Korman, B. Chen, C. Wang, L. Wu, P. Cardarelli, and M. Selby Activity of anti-PD-1 in murine tumor models: role of "host". PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4 J Immunol 179 2007 S82
3. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 2010 4275 4280
4. J. Duraiswamy, G.J. Freeman, and G. Coukos rapeutic PD-1 pathway blockade augments with or modalities of immunorapy T-cell function to prevent immune decline in ovarian cancer Cancer Res 73 2013 6900 6912
5. J. Matsuzaki, S. Gnjatic, P. Mhawech-Fauceglia, and et al. Tumor-infiltrating NY-ESO-1-specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer Proc Natl Acad Sci U S A 107 2010 7875 7880
6. J. Fourcade, Z. Sun, M. Benallaoua, and et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients J Exp Med 207 2010 2175 2186
7. L. Baitsch, A. Legat, L. Barba, and et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization PLoS ONE 7 2012 e30852
8. A.J. Zajac, J.N. Blattman, K. Murali-Krishna, and et al. Viral immune evasion due to persistence of activated T cells without effector function J Exp Med 188 1998 2205 2213
9. S.D. Blackburn, H. Shin, W.N. Haining, and et al. Coregulation of CD8+T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 10 2009 29 37
10. D. Pardoll, and C. Drake Immunorapy earns its spot in ranks of cancer rapy J Exp Med 209 2012 201 209
11. T.J. Lynch, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
12. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
13. J. Grosso, C.E. Horak, D. Inzunza, and et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) ASCO Meeting Abstracts 31 2013 3016
14. H.J. Hammers, E.R. Plimack, J.R. Infante, and et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) ASCO Meeting Abstracts 32 2014 4504
15. S.J. Antonia, S.N. Gettinger, L.Q.M. Chow, and et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results ASCO Meeting Abstracts 32 2014 8023
16. M.V. Goldberg, and C.G. Drake LAG-3 in cancer immunorapy Curr Top Microbiol Immunol 344 2011 269 278
17. F. Triebel, S. Jitsukawa, E. Baixeras, and et al. LAG-3, a novel lymphocyte activation gene closely related to CD4 J Exp Med 171 1990 1393 1405
18. E. Baixeras, B. Huard, C. Miossec, and et al. Characterization of lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens J Exp Med 176 1992 327 337
19. T. Miyazaki, A. Dierich, C. Benoist, and D. Mathis LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice Int Immunol 8 1996 725 729
20. J.F. Grosso, C.C. Kelleher, T.J. Harris, and et al. LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems J Clin Invest 117 2007 3383 3392
21. M. Bettini, A.L. Szymczak-Workman, K. Forbes, and et al. Cutting edge: Accelerated autoimmune diabetes in absence of LAG-3 J Immunol 187 2011 3493 3498
22. C.J. Workman, and D.A. Vignali CD4-related molecule, LAG-3 (CD223), regulates expansion of activated T cells Eur J Immunol 33 2003 970 979
23. C.T. Huang, C.J. Workman, D. Flies, and et al. Role of LAG-3 in regulatory T cells Immunity 21 2004 503 513
24. N.M. Durham, C.J. Nirschl, C.M. Jackson, and et al. Lymphocyte activation gene 3 (LAG-3) modulates ability of CD4 T-cells to be suppressed in vivo PLoS ONE 9 2014 e109080
25. E.I. Sega, D.B. Leveson-Gower, M. Florek, D. Schneidawind, R.H. Luong, and R.S. Negrin Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation PLoS ONE 9 2014 e86551
26. S.R. Woo, M.E. Turnis, M.V. Goldberg, and et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 2012 917 927
27. T. Okazaki, I.M. Okazaki, J. Wang, and et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice J Exp Med 208 2011 395 407
28. A. Sanchez-Fueyo, J. Tian, D. Picarella, and et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance Nat Immunol 4 2003 1093 1101
29. L. Monney, C.A. Sabatos, J.L. Gaglia, and et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease Nature 415 2002 536 541
30. C. Zhu, A.C. Anderson, A. Schubart, and et al. Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity Nat Immunol 6 2005 1245 1252
31. P.S. van de Weyer, M. Muehlfeit, C. Klose, J.V. Bonventre, G. Walz, and E.W. Kuehn A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9 Biochem Biophys Res Commun 351 2006 571 576
32. J. Weber Ipilimumab: Controversies in its development, utility and autoimmune adverse events Cancer Immunol Immunor 58 2009 823 830
33. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
34. G. Tiegs, and A.W. Lohse Immune tolerance: what is unique about liver J Autoimmun 34 2010 1 6
35. N.J. Llosa, M. Cruise, A. Tam, and et al. vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints Cancer Discov 5 2015 43 51